

BOARD OF PHARMACY
Professional & Vocational Licensing Division
Department of Commerce and Consumer Affairs
State of Hawaii

MINUTES OF MEETING

Date: Thursday, January 17, 2013

Time: 9:00 a.m.

Place: Queen Liliuokalani Conference Room
King Kalakaua Building
335 Merchant Street, First Floor
Honolulu, Hawaii 96813

Members Present: Mark E. Brown, Pharmacist, Chair
Patrick Adams, Pharmacist, Vice Chair
Garrett Lau, Pharmacist
Jill Oliveira Gray, Public Member
Todd Inafuku, Pharmacist
Lydia Kumasaka, Public Member
Carolyn Ma, Pharmacist

Staff Present: Lee Ann Teshima, Executive Officer ("EO")
Stephen Levins, Deputy Attorney General ("DAG")
Lisa Kalani, Secretary

Guests: Greg Edwards, Department of Health, Food and Drug Branch
Paul Sibley, Retina Institute of Hawaii
Debbie Shimabukuru, Retina Institute of Hawaii
Stacy Pi, Kaiser Permanente
Paul Smith, Walgreens
Rafael del Castillo, HCPA
Al Carter, Walgreens
Stacie Cooper, Cataract & Vision Center of Hawaii
Ron Walker, Eye Surgery Center of Hawaii

Agenda: The agenda for this meeting was filed with the Office of the Lieutenant Governor, as required by section 92-7(b), Hawaii Revised Statutes ("HRS").

Call to Order: There being a quorum present, the Chair called the meeting to order at 9:14 a.m.

Chair's Report: **Announcements and Introductions**

The Chair asked the audience to introduce themselves.

Additions/Additional Distribution to Agenda

The Chair called for a motion to add the following to today's agenda:

Upon a motion by the Vice Chair, seconded by Mr. Inafuku, it was voted on and unanimously carried to add the following to today's agenda:

Additions

- 5. Correspondence
 - a. National Association of Boards of Pharmacy ("NABP")
 - 6) NABP Newsletters
 - i. Louisiana Board of Pharmacy
 - ii. Nevada Board of Pharmacy
 - iii. South Dakota Board of Pharmacy

The Chair stated the following agenda items have additional distribution:

Additional Distribution

- 5. Correspondence
 - j. QMC West Pharmacy Planning, Selma Yamamoto
- 8 Applications
 - a. Ratification List
 - b. Applications
 - 1) 4th Street Pharmacy Inc., dba Compounding Pharmacy
 - 2) Harriet J. Manis Responding to Conditional Approval for DaVita Rx
- 9. Chapter 91, HRS, Adjudicatory Matters
 - a. Jodi M. Miller, PHA 2008-11-L, Monitor's Report for Period Covering November 2012 – January 2013

Approval of the Previous Minutes – December 20, 2012

The Chair called for a motion to approve the minutes of the December 20, 2012 meeting.

Dr. Ma stated on page 7, under "Remote Medication Order Processing, Kevin Jones", middle of the page, her statement should read as, "Dr. Ma stated that a pharmacist is always on call to ~~release medications~~ approve medications orders.

Mr. Lau stated on page 7, under "Remote Medication Order Processing, Kevin Jones", middle of the page, he believes the Chair made the statement about the PIXIS entry.

The Chair agreed and also asked that the word "dispense" be replaced with "administer" to reflect a more accurate statement.

Mr. Inafuku stated on page 8, under "Pharmacist Administration of Vaccines with Collaborating Physician, Steven Fukumoto" he recalled the Board referring this matter to the Laws and Rules Committee for further research and does not recall the Board agreeing that a prescription was required to dispense the drug to be administered by the pharmacist.

Dr. Ma and Mr. Lau stated that they recall the discussion and that they also researched one of the drugs listed to see if it was a legend drug and that the consensus appears to be correct and recommend that the following be stricken from the minutes, "in order for the pharmacist to administer the drug to the patient and that administration of any prescription drug by a pharmacist must be in compliance with the pharmacy laws and rules and any other applicable state or federal laws and regulations."

The Chair stated on page 2, under "Report of Experience as Disaster Medical Assistant Team Hawaii Sent to New York City for Hurricane Sandy Relief", he wanted to clarify that the team assisted at a "shelter" and not "rescued" people from a nursing home.

There being no further amendments or discussion, upon a motion by Mr. Inafuku, seconded by Dr. Oliveira Gray, it was voted on with the Chair, Mr. Inafuku, Mr. Lau, Dr. Ma, Dr. Oliveira Gray and Ms. Kumasaka voting to approve the minutes as amended and the Vice Chair abstaining since he was not present.

Mr. Inafuku requested that the Board refer the issue regarding dispensing/administration of a drug by a pharmacist pursuant to a prescription/collaborative agreement/standing order to the Laws and Rules Committee to research and discuss and report back to the Board.

Executive Officer's
Report:

2013 Legislature

The EO reported that she was just handed the following bills:

- HB 61 Relating to Pharmacy;
- HB 62 Relating to Pharmacy Benefit Managers;
- HB 63 Relating to Pharmacy;
- HB 64 Relating to Controlled Substances; and
- HB 65 Relating to Prescription Drugs

She asked that the members go to the State Capitol web page to review the bills and to email their comments to her so she could consolidate for the Board to discuss at their next open meeting.

The Vice Chair recommended that the February Board meeting be moved earlier in the month so that the Board will be able to review/discuss the bills at an open meeting and provide comments/recommendations to the Legislature in a timely manner.

Dr. Ma stated that on one hand its good to be prepared in case the bill is scheduled for hearing and the Board has had an opportunity to discuss and make recommendations, on the other hand its also advantages to see what happens after the initial hearing and the position of other stake holders.

After some discussion, upon a motion by the Vice Chair, seconded by Mr. Inafuku, it was voted on and unanimously carried to move the February Board meeting to **Friday, February 8, 2013** at 9:00 a.m. in the Queen Lilioukalani Conference Room.

The EO asked which Board members would not be able to attend, Dr. Oliveira Gray and the Chair stated they would not be able to attend.

Gregory Edwards, Department of Health, Food and Drug Branch Report

Mr. Edwards provided a verbal report on his attendance at the FDA Intergovernmental Meeting held in Washington, D.C. on December 19, 2012.

Mr. Edwards' summary included:

- Definitions for compounding and manufacturing must be established in federal and state statutes and regulations that are concise and uniform.
- Request from the states for FDA's participation in regional meetings and discussions and increased communication between the FDA and the states.
- The states need clarification of the FDA's registration of a manufacturer.
- Resources and special training in key areas are needed by the states to effectively assume new responsibilities discussed and to assist the FDA with the challenges currently being faced to develop the needed regulatory structure.
- State's want FDA to define compounding vs manufacturing.
- Compounding preservative free is a growing request from the public.

AI Carter Presentation, Walgreens Well Experience Pharmacy

Mr. Carter gave a brief overview of the "Walgreens Well Experience Pharmacy" which includes the following:

- Customer able to consult/speak with a pharmacist, face-to-face;
- Able to offer patient accessible care with secure access;
- Pharmacist able to supervise pharmacy technician workstation with live video feed, with the ability to globalize and enlarge area views;
- Additional video on pharmacy cashier area, drive-thru and express refill and pick areas;
- Drug product verified by pharmacist via video and at store level completes final product review.

The Board had concerns with:

- The security of the pharmacy premises and the inclusion or exclusion of the consult nook and having the public within the pharmacy area;
- Supervision of the pharmacy technician exclusively via video;
- Pharmacist final product review and initialing of final product.

After further discussion, it was the consensus of the Board that:

- The program presented must be in compliance with the pharmacy laws and rules, including but not limited to the pharmacist supervision of the pharmacy technician and other pharmacy personnel and the "initialing" of all prescriptions filled;
- Walgreens contact the Department of Public Safety, Narcotics Enforcement Division for compliance with HRS 329, the Uniform Controlled Substances Act;
- The Board accepts Walgreens offer to submit their policies and procedures for this program, not for Board approval but for informational purposes only;
- The Board be notified, in writing, of the implementation date for this program for Walgreens pharmacies located in this State; and
- Walgreens provide a status report 3-6 months after the implementation date on any issues, including comments from pharmacist working in this program in Hawaii.

At this time the Chair wish to take the agenda out-of-order and address item 5.c.

Correspondence:

Compounding for Ophthalmology

Dr. William Wong, Jr.

Ms. Cooper of Cataract & Vision Center of Hawaii and Mr. Walker of Eye Surgery Center of Hawaii introduced themselves on behalf of Dr. Wong.

The concern regarding the prescription requirement for a pharmacy to compound and dispense a product to be administered by an ophthalmologist would delay treatment to a patient which may result in permanent loss of vision and even loss of the eye itself.

Ms. Cooper stated that they order Avastin, a compounded product from Leiter Compounding Pharmacy out of California and keep a supply in their office for administration to their patients and that requiring a prescription to compound and dispense this product would be detrimental to the patient requiring immediate medication.

When asked if another product could be used or if a local pharmacy was able to compound the product, Ms. Cooper stated that the compounded product was less expensive and that she is unaware of any local compounding pharmacies.

After further discussion, it was the consensus of the Board that since this entity was located in another state and does not appear to be "dispensing" a prescription drug pursuant to a patient specific prescription, but perhaps acting as a wholesaler, the Board determined that their current laws and rules do not address out of state compounding pharmacies who are not dispensing prescription drugs directly to the end user/patient.

Letter from the American Academy of Ophthalmology

The same response above will be provided.

Letter from the American Society of Retina Specialist

The same response above will be provided.

Laws and Rules
Committee Report:

Mr. Inafuku reported what was discussed at the Committee meeting this morning:

- Request that the EO add "or chart order" after "prescription" in the draft of HRS 461;
- Discussion on the drafted language for a pharmacist diversion/impaired program;
- Refer to "registered pharmacist" throughout HRS 461; and
- NABP Task Force wants to encourage boards of pharmacy to incorporate language from the Model Act pertaining to the reporting of separation of employment of any pharmacist, pharmacy intern, pharmacy technician, or certified pharmacy technician. It was also recommended that the Committee research the possibility of regulating pharmacy technicians. The EO will be preparing a draft survey for the Committee's recommendation.

Correspondence:

National Association of Boards of Pharmacy ("NABP")

The Chair reported on the following:

NABP State News Roundup, December 2012

- The Iowa State Board of Pharmacy inspectors received assistance with inspections and surveys of controlled substances (CS) registrants for compliance with Iowa's criteria.
- The Kansas State Board of Pharmacy made several modifications to the Kansas Tracking and Reporting of CS. One of the amendments included changing the definition of "patient identification number." The patient identification number is the patient's unexpired or permanent driver's license number or state-issued identification care number. If the patient does not have one of these numbers, the pharmacy uses the patient's insurance identification number or if no insurance number, the dispenser uses the patient's first, middle, and last initials, followed by the patient's 8 digit birth date. The second amendment is related to those dispensers who have a "zero report" or no dispensing of CS or drugs. If the pharmacy has a zero report, they still need to report this every 7 days. If the dispenser does not file a report, it appears they have failed to report.
- The North Dakota Board of Pharmacy reported that the North Dakota Health Information Network Direct (NDHIND) went live March 2012. The NDHIND provides a secure, encrypted method of exchanging protected health information such as prescriptions, lab reports, consults, and other clinical information between providers, payors, health department, etc.
- Tennessee Board of Pharmacy reported that as of January 1, 2013, registrants have the option of being notified by email of renewals, fee increases, changes in state law, etc.

NABP e-News (12/20/12)

The Massachusetts Board of Pharmacy is revising their laws to clearly differentiate manufacturing pharmacies from compounding pharmacies. The article stated that one problem discovered in the New England Compounding Center (NECC) was that it operated as a manufacturing pharmacy but did not adhere to the Food and Drug Administration's Good Manufacturing Practices. The Board also plans to create a new license specifically for sterile compounding pharmacies and require accreditation.

Other articles in this issue also pertained to other Boards of Pharmacy and their efforts to tighten regulations for compounding pharmacies.

Another article focused on a recent study by the Winchester Medical Center involving pharmacists and pharmacy technicians in the hospital admissions process and how that reduced medication errors and improved the accuracy of electronic health records.

NABP e-News (1/9/2013)

This issue also had articles on the California and Minnesota Boards of Pharmacy's efforts to strengthen regulation and/or conduct more inspections on compounding pharmacies.

FDA Meeting Follow-Up

FDA held an intergovernmental meeting on December 19, 2012, which Mr. Edwards attended as well as an investigator from the Regulated Industries Complaints Office. The NABP identified some initial points for affirmation with the Commissioner and FDA that include:

- Definitions for compounding and manufacturing must be established in federal and state statutes and regulations that are concise and uniform;
- Bidirectional communication must occur between the FDA and the states, critical to the inspection of compounding pharmacies and manufacturers and when regulatory or disciplinary actions are initiated, pursued, or finalized;
- Resources and special training are key areas needed by the states to effectively regulate compounding pharmacies;
- States need clarification of FDA's registration of a manufacturer; and
- Concerns with the concept of "non-traditional" compounding since it is not defined in state statutes and may not be a concept the states will support as a third tier of drug production.

Solicitation of Community Pharmacies to Fill Invalid Online Prescriptions

The NABP sent out a notice warning jurisdictions of an illegal online drug seller that is soliciting community pharmacies to fill invalid prescriptions generated over the internet. An Illinois pharmacist received the solicitation via fax from National Rx Partners (www.nationalrespartners.com) asking him to fill 100 prescriptions a day and to act as a "fulfillment partner".

The EO stated that she checked the license database and this entity does not hold a Hawaii license/permit.

NABP Newsletters

- ***Louisiana Board of Pharmacy***
The Chair stated that the Louisiana Board of Pharmacy reported on the status of regulatory projects that affect institutional pharmacies (clarifying the definition of an institutional pharmacy to specifically exclude hospital pharmacies and penal pharmacies), interstate remote processing (amending the definition of the term "remote processor" to allow any permitted pharmacy to provide remote processing services for any other permitted pharmacy, regardless of location of either pharmacy and places new requirements on hospital pharmacies providing remote processing services as well as on pharmacies providing remote processing services to a hospital pharmacy, durable medical equipment permit (create a new classification of limited service pharmacy permits).

- ***Nevada Board of Pharmacy***
The Chair reported that based on the number of inquiries received by the Nevada Board of Pharmacy in regards to the delivery of prescriptions (drugs), they have developed some FAQs. The Board is also reminding their pharmacies and pharmacist about manufacturing vs. compounding.
- ***South Dakota Board of Pharmacy***
The Chair reported that the South Dakota Board of Pharmacy had an article about medication requests for "office use" and that a "Prescription drug order" must be for a specific patient and if a prescription is not patient-specific, is not valid. If a practitioner requests medication from a pharmacy, this transaction may be considered a wholesale distribution.

Miscellaneous Permits, Patrick Adams

The Vice Chair stated that based on the numerous inquiries coming before the Board regarding out-of-state pharmacies (miscellaneous permits), including mail order pharmacies, he would like to clarify if the out-of-state pharmacies, permitted to dispense drugs into this State, are compliant with Hawaii's pharmacy and drug laws.

Mr. Inafuku stated that pharmacists in Hawaii are allowed to fill an out-of-state prescription for non-controlled substances in accordance with Hawaii law and without being required to be licensed in the state that the prescription originated from.

The DAG asked if there is concern with out-of-state pharmacies being grossly deficient because if there is a concern, the Board of Pharmacy where the pharmacy is located is the authority to "police" that pharmacy.

The EO asked the Vice Chair if he is asking if the out-of-state pharmacy filling a prescription and dispensing the prescription drug into this State must comply with Hawaii laws and rules, including but not limited to the Board of Pharmacy, Department of Health, and Department of Public Safety.

The Vice Chair said yes.

The EO stated that this is a very important issue that should be discussed and addressed, but did not believe the Board had sufficient information to make a determination.

The Vice Chair stated he didn't expect a decision but wanted the Board to start thinking about this issue so that it can be discussed thoroughly.

Return of Drugs for Destruction, Nelson Nako

The Chair asked Mr. Lau to lead the discussion on Mr. Nako's email inquiry on the return of prescription drugs for destruction. Mr. Nako refers to HAR § 16-95-87 "Return or exchange of drugs prohibited." and asked if the intent is not to return or exchange but to take back for destruction, would a pharmacy be able to take the medication. These would be expired or discontinued medications from long term care facilities to a pharmacy contractor.

Dr. Ma stated that this is an issue that should be addressed.

The Vice Chair also stated that if the Board would allow a pharmacy to take back drugs, any exemptions would have to be specified.

After some discussion, it was the consensus of the Board to inform Mr. Nako that unfortunately, the current administrative rules do not allow a pharmacy to take back prescription drugs (non-controlled substances), not even for destruction.

Dispensing Question, Keith Sanderson

The Chair asked Dr. Ma to lead the discussion on the inquiry from Mr. Sanderson on the utilization of a pneumatic tube delivery system from their pharmacy to their Behavior Health Department of to another clinic on site. Mr. Sanderson asked, "that if an RN or clinic staff received the drug on the other end and dispensed it to the patient, is this script considered a clinic-dispensed drug?".

After some discussion, it was the consensus of the Board that once the drugs leave the pharmacy (via the pneumatic tube delivery system), it is considered "dispensed" which is defined in HRS 461-1, and that "delivery" is not defined in the pharmacy laws or rules and to clarify that a RN or clinic staff may not "dispense" a drug.

Compounding for "Office Use", James Fink

The Chair asked Ms. Kumasaka to lead the discussion on the email from Mr. Fink, Director of drug studies for Leiter's Compounding Pharmacy in San Jose, California requesting clarification on compounded drugs used by the prescriber in their office.

Mr. Fink stated that he understands Hawaii does not allow for "office use" dispensing and wants to know if there are any exceptions. In organizing drug studies, there are potential patients in our State that would like to enroll in their studies, however, the timing often dictates that the drug needs to be at the facility at the time the patient is enrolled. He also asked if there are any additional exceptions such as diagnostic eye drops that will be used on multiple patients or medications to treat emergency situations. And lastly, if they are working on a blinded study often the patients are identified with a randomization number where all documentation is kept and would this satisfy our state requirements for being patient specific.

Mr. Inafuku stated that they may be exempt pursuant to HRS §328-17.

Mr. Edwards stated that there are no administrative rules for the exemptions under HRS §328-17.

After some discussion, it was the consensus of the Board that since this entity was located in another state and does not appear to be "dispensing" a prescription drug pursuant to a patient specific prescription, but perhaps acting as a wholesaler, the Board determined that their current laws and rules do not address out of state compounding pharmacies who are not dispensing prescription drugs directly to the end use/patient.

E-Prescribing and Marketing Regulations, Daniel Rickert

The Chair asked Mr. Inafuku to lead the discussion on the email from Mr. Rickert which included 4 questions pertaining to e-prescribing and advertising by drug companies to prescribers.

After some discussion, it was the consensus of the Board to respond to the following questions as indicated below:

1. Are there any laws or regulations specific to e-prescribing standards or use? (The focus of this question is the use of computer software for e-prescribing – not faxed prescriptions)

Response: The Board refers to HRS 328-16, 328-17.8 and 328-17.9 in regards to e-prescribing, which falls under the authority of the Department of Health, Food and Drug Branch.

2. Are there any laws or regulations that address the use of commercial messaging within a e-prescribing program/Ad-supported e-prescribing software?

Response: Not addressed.

3. Are there laws or regulations that govern direct advertising by drug companies to prescribers?

Response: Not addressed.

4. Is there any pending legislation or board rules regarding e-prescribing or pharmaceutical marketing that are under consideration in Hawaii?

Response: Not at this time.

Compounding Pharmacy, Daniel P. Blakeley

Chair reported that in a letter from Mr. Blakeley, Foundation Care will be providing “services” to patients in this State, that includes specialty products for patients suffering from cystic fibrosis and other chronic respiratory diseases that include compounded medications based on a physician’s order and patient’s prescription. Mr. Blakeley provided a copy of Foundation Care’s Pharmacy Compounding Accreditation Board accreditation.

Mr. Blakeley also stated that Foundation Care will be compounding Human Legend Drugs for veterinary use, pursuant to a licensed veterinarian’s prescription.

Foundation Care, LLC, dba Foundation Care currently holds a miscellaneous permit as an out-of-state pharmacy.

Request for Waiver of Non-Resident Pharmacy Permit, Terry Isler

The Chair reported that, Ms. Isler, Pharmacy Manager for Pharmacy Specialists Compounding Pharmacy submitted a request to waive the permit and licensing requirements for their non-resident pharmacy located in Florida. She stated that their pharmacy is accredited by the PCAB as a compounding pharmacy and that they are a local community compounding pharmacy that focuses on servicing Central Florida physicians and patients and do not plan to solicit or market for business.

After some discussion, it was the consensus of the Board that the Board does not have the authority to waive or exempt Pharmacy Specialists Compounding Pharmacy from the license/permit requirements. If Pharmacy Specialists Compounding Pharmacy wants to dispense prescription drugs into this State, directly to the end user/patient, they must obtain a miscellaneous permit as an out-of-state pharmacy.

QMC West Pharmacy Planning, Selma Yamamoto

The Chair stated that Ms. Yamamoto had some questions regarding the compounding, packaging of medications (bulk to unit dose format) to be used at the QMC West facility and remote order verifications at QMC Honolulu for QMC West when the pharmacy at QMC West is closed.

After some discussion, it was the consensus of the Board that no permit is required to "prepack" your own stock of prescription drugs and assuming that QMC Honolulu and QMC West are under common ownership. In regards to the compounding of sterile products to be used at the QMC West, a pharmacy may dispense a drug, including compounded drugs, pursuant to a patient specific prescription and in an appropriately labeled container. And lastly, performing remote order verification at QMC Honolulu for QMC West, assuming both are under common ownership, this may be permissible.

Old Business: **HAR Title 16, Chapter 95 – Status Report**

No report.

Open Forum: Mr. Inafuku requested that the Board review a "State of Emergency" procedure at their February 2013 meeting.

Applications: **Ratification List**

Upon a motion by the Vice Chair, seconded by Mr. Inafuku, it was voted on and unanimously carried to approve the attached ratification lists.

Executive Session: At 12:42 p.m., upon a motion by the Vice Chair, seconded by Mr. Inafuku, it was voted on and unanimously carried to move into executive session pursuant to §92-5(a)(1) and (4), HRS, "to consider and evaluate personal information relating to individuals applying for professional or vocational licenses cited in section 26-9 or both;" and "To consult with the Board's attorney on questions and issues pertaining to the board's powers, duties, privileges, immunities, and liabilities;".

At 12:45 p.m. upon a motion by Dr. Oliveira Gray, seconded by Ms. Kumasaka, it was voted on and unanimously carried to move out of executive session.

Chapter 91, HRS,
Adjudicatory Matters:

At 12:45 p.m. the Chair called for a recess from the Board's meeting to discuss and deliberate on the following adjudicatory matter, pursuant to Chapter 91, HRS:

In the Matter of the Pharmacist's License of Lori M. Brandt: PHA 2010-44-L. Settlement Agreement after Filing of Petition for Disciplinary Action and Board's Final Order. Exhibit "1"

Upon a motion by the Vice Chair, seconded by Dr. Ma, it was voted on and unanimously carried to accept the Board's Final Order.

In the Matter of the Pharmacist's License of Imelda D. Osten: PHA 2010-45-L. Hearings Officer's Finding of Fact, Conclusions of Law and Recommended Order.

Upon a motion by the Vice Chair, seconded by Dr. Oliveira Gray, it was voted on and unanimously carried to accept the Recommended Order.

Jodi M. Miller, PHA 2008-11-L, Monitor's Report for Period Covering November 2012 – January 2013

Upon a motion by the Chair, seconded by the Vice Chair, it was voted on and unanimously carried to accept the monitor's report for the period covering November 2012 – January 2013 with the next report for the period covering February – April 2013 due for the Board's consideration at their May 16, 2013 meeting.

Following the Board's review, deliberation and decision on these matters, pursuant to Chapter 91, HRS, The Chair announced that the Board was reconvening its scheduled meeting at 1:50 p.m.

Applications:

Applications

Upon a motion by the Vice Chair, seconded by Dr. Oliveira Gray, it was voted on and unanimously carried to approve the miscellaneous permit indicated below with the condition that John Grasela may not fill or compound any prescriptions coming into this State based on his prior disciplinary action with the California Board of Pharmacy.

4th Street Pharmacy Inc. dba University Compounding Pharmacy

Upon a motion by the Vice Chair, seconded by Ms. Kumasaka, it was voted on and unanimously carried to inform Ms. Manis that the Board could not consider her request for reconsideration as she was not the applicant.

Next Meeting: **Friday, February 8, 2013 – New Date**
9:00 a.m.
Queen Lilioukalani Conference Room – New Room
King Kalakaua Building, First Floor
335 Merchant Street
Honolulu, Hawaii 96813

Dr. Oliveira Gray and the Chair stated they would not be able to attend the meeting.

Adjournment: With no further business to discuss, the Chair adjourned the meeting at 1:51 p.m.

Reviewed and approved by:

Taken and recorded by:

/s/ Lee Ann Teshima
Lee Ann Teshima,
Executive Officer

/s/ Lisa Kalani
Lisa Kalani,
Secretary

1/22/13

Minutes approved as is.
 Minutes approved with changes; see minutes of _____

LTYPE	LIC NUM	BP NAME PART 1
PH	3459	WESLEY K <CHING<
PH	3460	SHEENA A K <CABREROS<
PH	3461	KIM T T <NGUYEN<
PH	3462	NAUFEL F <TAJUDEEN<
PH	3463	JENNIFER M L <LOO<
PH	3464	THY ANH <NGUYEN<

LTYPE	TEMP	LIC	NUM	VAM_BPR_LEGAL_NAME_1
PHI	3254			ERICA N <GRANT<
PHI	3250			NOAH J <STALCUP<
PHI	3253			NATHANIEL A <HEDRICK<
PHI	3252			CARLY D <HARTMAN<
PHI	3251			SHARMIE MAE S <UY<

LTYPE	LIC NUM	LIC NAME PART 1	BUSN ADDR 1	BUSN CITY	BUSN		
					ST	BUSN ZIP	BP NAME PART 1
PHY	829		1824 DILLINGHAM BLVD #B	HONOLULU	HI	96819	5 MINUTE PHARMACY KALIHI LLC

LTYPE	LIC NUM	LIC NAME PART 1	BUSN ADDR 1	BUSN CITY	BUSN		
					ST	BUSN ZIP	BP NAME PART 1
PMP	809		319 GARLINGTON RD STE D-4	GREENVILLE	SC	29615	MANIFEST PHARMACY LLC
PMP	810		14901 NW 79TH CT	MIAMI LAKES	FL	33016	WALGREEN CO
PMP	811		512 ELMWOOD AVE	SHARON HILL	PA	19079	EXCELLERX-PA D/B/A HOSPICE PHARMAC
PMP	812	EPHARMPRO SERVICES	3605B EDMONT AVE	BROOKHAVEN	PA	19015	STELTEC PHARMACY
PMP	813		465 N ROXBURY DR	BEVERLY HILLS	CA	90210	ROXSAN PHARMACY INC
PMP	814		4399 NW 124TH AVE	CORAL SPRINGS	FL	33065	PLAZA PHARMACY INC
PMP	815	EAGLE PHARMACY	500 EAGLE LANDING DR STE C	LAKELAND	FL	33810	EAGLE PHARMACY LLC
PMP	816		304 1/2 CHARLIE DR	WHITESBORO	TX	76273	AXTELL RITE VALUE PHARMACY INC